Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, Ohio, USA.
Haematologica. 2013 Jan;98(1):107-13. doi: 10.3324/haematol.2012.064048. Epub 2012 Jul 6.
Chronic myelomonocytic leukemia is a heterogeneous disease with multifactorial molecular pathogenesis. Various recurrent somatic mutations have been detected alone or in combination in chronic myelomonocytic leukemia. Recently, recurrent mutations in spliceosomal genes have been discovered. We investigated the contribution of U2AF1, SRSF2 and SF3B1 mutations in the pathogenesis of chronic myelomonocytic leukemia and closely related diseases. We genotyped a cohort of patients with chronic myelomonocytic leukemia, secondary acute myeloid leukemia derived from chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia for somatic mutations in U2AF1, SRSF2, SF3B1 and in the other 12 most frequently affected genes in these conditions. Chromosomal abnormalities were assessed by nucleotide polymorphism array-based karyotyping. The presence of molecular lesions was correlated with clinical endpoints. Mutations in SRSF2, U2AF1 and SF3B1 were found in 32%, 13% and 6% of cases of chronic myelomonocytic leukemia, secondary acute myeloid leukemia derived from chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia, respectively. Spliceosomal genes were affected in various combinations with other mutations, including TET2, ASXL1, CBL, EZH2, RAS, IDH1/2, DNMT3A, TP53, UTX and RUNX1. Worse overall survival was associated with mutations in U2AF1 (P=0.047) and DNMT3A (P=0.015). RAS mutations had an impact on overall survival in secondary acute myeloid leukemia (P=0.0456). By comparison, our screening of juvenile myelomonocytic leukemia cases showed mutations in ASXL1 (4%), CBL (10%), and RAS (6%) but not in IDH1/2, TET2, EZH2, DNMT3A or the three spliceosomal genes. SRSF2 and U2AF1 along with TET2 (48%) and ASXL1 (38%) are frequently affected by somatic mutations in chronic myelomonocytic leukemia, quite distinctly from the profile seen in juvenile myelomonocytic leukemia. Our data also suggest that spliceosomal mutations are of ancestral origin.
慢性髓单核细胞白血病是一种具有多因素分子发病机制的异质性疾病。已经单独或组合检测到各种复发性体细胞突变存在于慢性髓单核细胞白血病中。最近,发现剪接体基因中存在复发性突变。我们研究了 U2AF1、SRSF2 和 SF3B1 突变在慢性髓单核细胞白血病及其密切相关疾病发病机制中的作用。我们对一组慢性髓单核细胞白血病、由慢性髓单核细胞白血病衍生的继发性急性髓细胞白血病和幼年髓单核细胞白血病患者进行了 U2AF1、SRSF2、SF3B1 和这些疾病中其他 12 个最常受影响基因的体细胞突变分析。通过基于核苷酸多态性阵列的核型分析评估染色体异常。将分子病变的存在与临床终点相关联。在慢性髓单核细胞白血病、由慢性髓单核细胞白血病衍生的继发性急性髓细胞白血病和幼年髓单核细胞白血病中分别发现 SRSF2、U2AF1 和 SF3B1 突变分别占 32%、13%和 6%。剪接体基因与其他突变(包括 TET2、ASXL1、CBL、EZH2、RAS、IDH1/2、DNMT3A、TP53、UTX 和 RUNX1)以各种组合的形式受到影响。U2AF1(P=0.047)和 DNMT3A(P=0.015)突变与总体生存较差相关。RAS 突变对继发性急性髓细胞白血病的总体生存有影响(P=0.0456)。相比之下,我们对幼年髓单核细胞白血病病例的筛查显示,ASXL1(4%)、CBL(10%)和 RAS(6%)发生突变,但 IDH1/2、TET2、EZH2、DNMT3A 或三个剪接体基因未发生突变。SRSF2 和 U2AF1 以及 TET2(48%)和 ASXL1(38%)在慢性髓单核细胞白血病中经常发生体细胞突变,与幼年髓单核细胞白血病中的突变谱明显不同。我们的数据还表明,剪接体突变具有祖先起源。